See today's BioWorld Asia
To read the full story, subscribe or sign in.

Raynovent nets $54M in series C round for COVID-19, influenza A virus

Jan. 10, 2023
By Doris Yu
Raynovent Biotech Co. Ltd. has raised ¥370 million (US$54 million) in a series C round to further develop candidates in the field of respiratory and metabolic diseases.
BioWorld Asia Financings Infection Series C China